Global Hereditary Angioedema Therapeutic Market Size study & Forecast, by Drug Class (C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others), By Treatment Type (Prophylaxis, On-demand), By Route of Administration (Intraven

Global Hereditary Angioedema Therapeutic Market Size study & Forecast, by Drug Class (C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others), By Treatment Type (Prophylaxis, On-demand), By Route of Administration (Intravenous, Subcutaneous, Oral) and Regional Analysis, 2023-2030

Global Hereditary Angioedema Therapeutic Market is valued at approximately USD 4.42 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 8.5% over the forecast period 2023-2030. Hereditary angioedema is a rare genetic disorder that causes recurrent episodes of swelling in various parts of the body, including the face, throat, limbs, and abdomen. These attacks can be severe and life-threatening if they involve the airway. The Hereditary Angioedema Therapeutic market is expanding because of factors such as rising prevalence of genetic disorders and increasing adoption of novel therapeutics. Androgens are hormones that can increase the production of C1 inhibitors and reduce the frequency and severity of HAE attacks. However, they have significant side effects, including masculinization in women and children, liver toxicity, and an increased risk of blood clots. Its prevalence has progressively increased during the last few decades.

According to the World Health Organization, Genetic disorders and congenital abnormalities occur in about 2%-5% of all live births, accounting for up to 30% of pediatric hospital admissions, and cause about 50% of childhood deaths in industrialized countries. Furthermore, as per Statista, in 2020 Europe conducted a survey and found that 36% of respondents in the United Kingdom were unaware of the significance heredity plays in a person's proclivity to hereditary disorders. Another important component driving space is increasing adoption of novel therapeutics. According to Statista, the top therapy areas worldwide is projected to spend on is about USD 377 billion on oncology followed by immunology is projected to be second with around USD 177 billion of spending. In addition, in 2022, Wave Life Sciences Ltd had a strategic collaboration to advance oligonucleotide therapeutics, including Wave's preclinical RNA editing program. The initial research duration for the discovery collaboration is four years. GSK's unique human genetic insights, as well as its global development and commercial capabilities, are combined with Wave's patented discovery and medication development platform, PRISMTM. Also, advancements in formulation and technological advancement in drugs related to angioedema would create a lucrative growth prospectus for the market over the forecast period. However, lack of awareness about hereditary angioedema therapeutics stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Hereditary Angioedema Therapeutic Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the presence of key market players in the region. According to Statista, North America dominated the worldwide cell and gene therapy industry in 2020, accounting for about 56% of the total market and expected to increase at a rate of 33.8% between 2021 and 2027. Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising geriatric and target populations, and active participation of government and nonprofit organizations in the market space.

Major market players included in this report are:
CSL Limited
Takeda Pharmaceutical Company Limited
Pharming Healthcare Inc
Sanofi S.A.
BioCryst Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc
Shire Plc
Attune Pharmaceuticals, Inc
Adverum Biotechnologies, Inc
KalVista Pharmaceuticals, Inc

Recent Developments in the Market:
In March 2023, Sanofi SA intended to pay $2.9 billion for Provention Bio Inc in order to boost its therapeutic pipeline. Sanofi would get complete ownership of Tzield, a medicine that was authorized in the United States for delaying the onset of type 1 diabetes's third and final stage.

Global Hereditary Angioedema Therapeutic Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Drug Class, Treatment Type, Route of Administration, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Drug Class
C1-esterase inhibitor
Bradykinin B2 receptor antagonist
Kallikrein inhibitor
Others

By Treatment Type
Prophylaxis
On-demand

By Route of Administration
Intravenous
Subcutaneous
Oral

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
CSL Limited
Takeda Pharmaceutical Company Limited
Pharming Healthcare Inc
Sanofi S.A.
BioCryst Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc
Shire Plc
Attune Pharmaceuticals, Inc
Adverum Biotechnologies, Inc
KalVista Pharmaceuticals, Inc

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.